Review of treatment options for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) remains the most common chronic liver disease in the western world and its prevalence is rising elsewhere. Among patients with NAFLD, those with nonalcoholic steatohepatitis (NASH) represent a large potential public health concern with risk for development of cirrhosis and hepatocellular carcinoma. The ability to diagnose and treat NAFLD and NASH has improved and continues to improve as understanding of the pathogenesis of this disease develops. This article highlights the key features of NAFLD and NASH, as well as the available and future promising treatment options.